Article Listing - Biotechnology
Clinical success rates for new cancer drugs doubled from the mid-1990s to early-2000s, says Tufts CSDD
8 May 2013
Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000s, while the number of new cancer drugs entering clinical testing increased 50 percent during the same time, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.
BioCity to develop BioHub at Alderley Park post AstraZeneca
7 May 2013
BioCity Nottingham, a UK provider of life sciences business incubation services, has been appointed by AstraZeneca (LSE: AZN) to establish a new center for bioscience companies at Alderley Park in Cheshire, which the Anglo-Swedish drug major has revealed it will vacate as part of a restructuring (The Pharma Letter March 19). The BioHub will initially provide 36,000 sq ft of high-end laboratory and office facilities for early-stage and growing firms engaged in innovative drug discovery and development. The aim is to secure a sustainable future for the site.
Biotech industry has "implementation gap" around demonstrating the value of products under development
7 May 2013
Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment for the rest of the industry and an urgent need to focus on demonstrating value, comments trade group EuropaBio.
Concert Pharma in $300 million-plus deal with Celgene
7 May 2013
Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a strategic collaboration with fellow USA-based biotech Celgene (Nasdaq: CELG) directed towards deuterium-modified compounds targeting cancer and inflammation. The collaboration will initially focus on one program, but has the potential to encompass multiple targets.
Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx
6 May 2013
US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5kg.
Regeneron acquires rights to two ophthalmology programs from Sanofi
3 May 2013
US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in the company's antibody collaboration with French drug major Sanofi (Euronext: SAN).
Acceleron and Shire not to restart ACE-031 program
3 May 2013
Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has concluded its collaboration on ACE-031 and related molecules. The clinical development of ACE-031 was suspended in February 2011 and since then the companies have conducted preclinical studies to determine whether to resume clinical studies.
Pharma and biotech industries headed toward era of reduced profit margins
3 May 2013
In the face of reduced profit margins for the pharmaceutical and biotechnology sectors, an effective financial management strategy is central to maintain sustainable growth, according to a new report from market research firm Frost & Sullivan.
Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program
3 May 2013
US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013 increased 11% to $2.53 billion compared to the first quarter of 2012. Product sales increased 8% to $2.39 billion.
FDA advisory votes against AVEO and Astellas' cancer drug tivozanib
3 May 2013
US biotech firm AVEO Oncology (Nasdaq: AVEO) saw its shares plunge as much as 57% in late trading yesterday (May 2), after the stock was suspended ahead of a Food and Drug Administration advisory panel which, at the end of the day, gave a negative opinion for the company's cancer drug tivozanib. The stock closed down 49.6% at $2.65.
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
